Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies

References

• Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr Rev. 2020;41(1):66–18. doi:10.1210/endrev/bnz009.
   Web of Science ®Google Scholar
• Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut Preprint At. 2020;69(9):1691–1705. doi:10.1136/gutjnl-2020-320622.
   Google Scholar
• Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, Loomba R, Chalasani N, Kowdley K, Hameed B, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559–1569. doi:10.1056/NEJMoa2029349.
   PubMed Web of Science ®Google Scholar
• Meijnikman AS, Gerdes VE, Nieuwdorp M, Herrema H. Evaluating causality of gut microbiota in obesity and diabetes in humans. Endocr Rev. 2018;39(2):133–153. doi:10.1210/er.2017-00192.
   PubMed Web of Science ®Google Scholar
• Lane N. The unseen world: reflections on Leeuwenhoek (1677) ‘Concerning little animals’. Phil Trans R Soc B: Biol Sci. 2015;370(1666):20140344. doi:10.1098/rstb.2014.0344.
   PubMed Web of Science ®Google Scholar
• Young VB. The role of the microbiome in human health and disease: an introduction for clinicians. BMJ. 2017;356. Online Preprint at. doi:10.1136/bmj.j831.
   Google Scholar
• Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009;136. doi:10.1053/j.gastro.2008.10.080.
   PubMed Web of Science ®Google Scholar
• Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17(5):279–297. doi:10.1038/s41575-020-0269-9.
   PubMed Web of Science ®Google Scholar
• Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. doi:10.1097/HEP.0000000000000323.
   PubMed Web of Science ®Google Scholar
• Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo‐Perez F, Guy CD, Seed PC, Rawls JF, David LA, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–775. doi:10.1002/hep.28356.
   PubMed Web of Science ®Google Scholar
• Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25(5):1054–1062.e5. doi:10.1016/j.cmet.2017.04.001.
   PubMed Web of Science ®Google Scholar
• Meijnikman AS, Lappa D, Herrema H, Aydin O, Krautkramer KA, Tremaroli V, Olofsson LE, Lundqvist A, Bruin S, Acherman Y, et al. A systems biology approach to study non-alcoholic fatty liver (NAFL) in women with obesity. iScience. 2022;25(8):104828. doi:10.1016/j.isci.2022.104828.
   PubMed Web of Science ®Google Scholar
• Hoyles L, Fernández-Real J-M, Federici M, Serino M, Abbott J, Charpentier J, Heymes C, Luque JL, Anthony E, Barton RH, et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med. 2018;24(7):1070–1080. doi:10.1038/s41591-018-0061-3.
   PubMed Web of Science ®Google Scholar
• Caussy C, Tripathi A, Humphrey G, Bassirian S, Singh S, Faulkner C, Bettencourt R, Rizo E, Richards L, Xu ZZ, et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun. 2019;10(1):1406. doi:10.1038/s41467-019-09455-9.
   PubMedGoogle Scholar
• Caussy C, Hsu C, Lo M-T, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L, et al. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018;68(3):918–932. doi:10.1002/hep.29892.
   PubMed Web of Science ®Google Scholar
• Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25(5):1054–1062. doi:10.1016/j.cmet.2017.04.001.
   PubMed Web of Science ®Google Scholar
• Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba EV, Bettencourt R, Richards L, et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab. 2020;32(5):901. doi:10.1016/j.cmet.2020.06.005.
   PubMed Web of Science ®Google Scholar
• Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and meta-analysis. Lipids Health Dis. 2021;20. doi:10.1186/s12944-021-01440-w.
   Web of Science ®Google Scholar
• Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, Almeida M, Quinquis B, Levenez F, Galleron N, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500(7464):585–588. doi:10.1038/nature12480.
   PubMed Web of Science ®Google Scholar
• Pekkala S. Fecal metagenomics and metabolomics identifying microbial signatures in non-alcoholic fatty liver disease. Int J Mol Sci. 2023;24(5):4855. doi:10.3390/ijms24054855.
   PubMed Web of Science ®Google Scholar
• SR S, B S, R K, R L. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell Metab. 2021;33(1):21–32. doi:10.1016/j.cmet.2020.11.010.
   PubMed Web of Science ®Google Scholar
• Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? revisiting the ratio of bacterial to host cells in humans. Cell. 2016;164:337–340. doi:10.1016/j.cell.2016.01.013.
   PubMed Web of Science ®Google Scholar
• Tierney BT, Yang Z, Luber JM, Beaudin M, Wibowo MC, Baek C, Mehlenbacher E, Patel CJ, Kostic AD. The landscape of genetic content in the gut and oral human microbiome. Cell Host & Microbe. 2019;26(2):283–295.e8. doi:10.1016/j.chom.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, Mujagic Z, Vila AV, Falony G, Vieira-Silva S, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Sci (1979). 2016;352(6285):565–569. doi:10.1126/science.aad3369.
   PubMed Web of Science ®Google Scholar
• Asnicar F, Berry SE, Valdes AM, Nguyen LH, Piccinno G, Drew DA, Leeming E, Gibson R, Le Roy C, Khatib HA, et al. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nat Med. 2021;27(2):321–332. doi:10.1038/s41591-020-01183-8.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhernakova DV, Kurilshikov A, Andreu-Sánchez S, Wang D, Augustijn HE, Vich Vila A, Weersma RK, Medema MH, Netea MG, et al. Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome. Nat Med. 2022;28(11):2333–2343. doi:10.1038/s41591-022-02014-8.
   PubMed Web of Science ®Google Scholar
• Hughes DA, Bacigalupe R, Wang J, Rühlemann MC, Tito RY, Falony G, Joossens M, Vieira-Silva S, Henckaerts L, Rymenans L, et al. Genome-wide associations of human gut microbiome variation and implications for causal inference analyses. Nat Microbiol. 2020;5(9):1079–1087. doi:10.1038/s41564-020-0743-8.
   PubMed Web of Science ®Google Scholar
• Deschasaux M, Bouter KE, Prodan A, Levin E, Groen AK, Herrema H, Tremaroli V, Bakker GJ, Attaye I, Pinto-Sietsma S-J, et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat Med. 2018;24:1526–1531. doi:10.1038/s41591-018-0160-1.
   PubMed Web of Science ®Google Scholar
• Meijnikman AS, Aydin O, Prodan A, Tremaroli V, Herrema H, Levin E, Acherman Y, Bruin S, Gerdes VE, Backhed F, et al. Distinct differences in gut microbial composition and functional potential from lean to morbidly obese subjects. J Intern Med. 2020;288(6):699–710. doi:10.1111/joim.13137.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Ng SC, Schnabl B. Promises of microbiome-based therapies. J Hepatol. 2022;76(6):1379–1391. doi:10.1016/j.jhep.2021.12.003.
   PubMed Web of Science ®Google Scholar
• Brugère JF, Borrel G, Gaci N, Tottey W, O’Toole PW, Malpuech-Brugère C. Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. Gut Microbes. 2013;5(1):5–10. doi:10.4161/gmic.26749.
   PubMed Web of Science ®Google Scholar
• Ramezani A, Nolin TD, Barrows IR, Serrano MG, Buck GA, Regunathan-Shenk R, West RE, Latham PS, Amdur R, Raj DS. Gut colonization with methanogenic archaea lowers plasma trimethylamine n-oxide concentrations in apolipoprotein e−/− mice. Sci Rep. 2018;8(1). doi:10.1038/s41598-018-33018-5.
   Google Scholar
• Demir M, Lang S, Hartmann P, Duan Y, Martin A, Miyamoto Y, Bondareva M, Zhang X, Wang Y, Kasper P, et al. The fecal mycobiome in non-alcoholic fatty liver disease. J Hepatol. 2022;76(4):788–799. doi:10.1016/j.jhep.2021.11.029.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Liu EJ, Kheradman R, Fagan A, Heuman DM, White M, Gavis EA, Hylemon P, Sikaroodi M, Gillevet PM. Fungal dysbiosis in cirrhosis. Gut. 2018;67(6):1146–1154. doi:10.1136/gutjnl-2016-313170.
   PubMed Web of Science ®Google Scholar
• Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017;127(7):2829–2841. doi:10.1172/JCI90562.
   PubMed Web of Science ®Google Scholar
• Duan Y, Young R, Schnabl B. Bacteriophages and their potential for treatment of gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2022;19:135–144. doi:10.1038/s41575-021-00536-z.
   PubMed Web of Science ®Google Scholar
• Khan Mirzaei M, Xue J, Costa R, Ru J, Schulz S, Taranu ZE, Deng L. Challenges of studying the human virome – relevant emerging technologies. Trends Microbiol. 2021;29:171–181. doi:10.1016/j.tim.2020.05.021.
   PubMed Web of Science ®Google Scholar
• Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, et al. Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology. 2020;159(5):1839–1852. doi:10.1053/j.gastro.2020.07.005.
   PubMed Web of Science ®Google Scholar
• Hsu CL, Duan Y, Fouts DE, Schnabl B. Intestinal virome and therapeutic potential of bacteriophages in liver disease. J Hepatol. 2021;75(6):1465–1475. doi:10.1016/j.jhep.2021.08.003.
   PubMed Web of Science ®Google Scholar
• de Jonge PA, Wortelboer K, Scheithauer TPM, van den Born BJH, Zwinderman AH, Nobrega FL, Dutilh BE, Nieuwdorp M, Herrema H. Gut virome profiling identifies a widespread bacteriophage family associated with metabolic syndrome. Nat Commun. 2022;13(1). doi:10.1038/s41467-022-31390-5.
   Web of Science ®Google Scholar
• Yang K, Niu J, Zuo T, Sun Y, Xu Z, Tang W, Liu Q, Zhang J, Ng EKW, Wong SKH, et al. Alterations in the gut virome in obesity and type 2 diabetes mellitus. Gastroenterology. 2021;161(4):1257–1269.e13. doi:10.1053/j.gastro.2021.06.056.
   PubMed Web of Science ®Google Scholar
• Ma Y, You X, Mai G, Tokuyasu T, Liu C. A human gut phage catalog correlates the gut phageome with type 2 diabetes. Microbiome. 2018;6. doi:10.1186/s40168-018-0410-y.
   Web of Science ®Google Scholar
• Lawrence D, Baldridge MT, Handley SA. Phages and human health: more than idle hitchhikers. Viruses. 2019;11(7):587. Preprint at. doi:10.3390/v11070587.
   PubMed Web of Science ®Google Scholar
• Garmaeva S, Sinha T, Kurilshikov A, Fu J, Wijmenga C, Zhernakova A. Studying the gut virome in the metagenomic era: challenges and perspectives. BMC Biol. 2019;17(1). Preprint at. doi:10.1186/s12915-019-0704-y.
   PubMed Web of Science ®Google Scholar
• Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, Kotler E, Zur M, Regev-Lehavi D, Brik RBZ, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. 2018;174(6):1388–1405.e21. doi:10.1016/j.cell.2018.08.041.
   PubMed Web of Science ®Google Scholar
• Vaga S, Lee S, Ji B, Andreasson A, Talley NJ, Agréus L, Bidkhori G, Kovatcheva-Datchary P, Park J, Lee D, et al. Compositional and functional differences of the mucosal microbiota along the intestine of healthy individuals. Sci Rep. 2020;10(1):1–12. doi:10.1038/s41598-020-71939-2.
   PubMed Web of Science ®Google Scholar
• Shalon D, Culver RN, Grembi JA, Folz J, Treit PV, Shi H, Rosenberger FA, Dethlefsen L, Meng X, Yaffe E, et al. Profiling the human intestinal environment under physiological conditions. Nature. 2023;617(7961):581–591. doi:10.1038/s41586-023-05989-7.
   PubMed Web of Science ®Google Scholar
• Herrema H, Niess JH. Intestinal microbial metabolites in human metabolism and type 2 diabetes. Diabetologia. 2020;63(12):2533–2547. doi:10.1007/s00125-020-05268-4.
   PubMed Web of Science ®Google Scholar
• Talmor-Barkan Y, Bar N, Shaul AA, Shahaf N, Godneva A, Bussi Y, Lotan-Pompan M, Weinberger A, Shechter A, Chezar-Azerrad C, et al. Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease. Nat Med. 2022;28(2):295–302. doi:10.1038/s41591-022-01686-6.
   PubMed Web of Science ®Google Scholar
• Olofsson LE, Bäckhed F. The metabolic role and therapeutic potential of the microbiome. Endocr Rev. 2022;43(5):907–926. doi:10.1210/endrev/bnac004.
   PubMed Web of Science ®Google Scholar
• Koh A, Molinaro A, Ståhlman M, Khan MT, Schmidt C, Mannerås-Holm L, Wu H, Carreras A, Jeong H, Olofsson LE, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell. 2018;175(4):947–961.e17. doi:10.1016/j.cell.2018.09.055.
   PubMed Web of Science ®Google Scholar
• Nemet I, Saha PP, Gupta N, Zhu W, Romano KA, Skye SM, Cajka T, Mohan ML, Li L, Wu Y, et al. A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors. Cell. 2020;180(5):862–877.e22. doi:10.1016/j.cell.2020.02.016.
   PubMed Web of Science ®Google Scholar
• Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–1584. doi:10.1056/NEJMoa1109400.
   PubMed Web of Science ®Google Scholar
• Haghikia A, Zimmermann F, Schumann P, Jasina A, Roessler J, Schmidt D, Heinze P, Kaisler J, Nageswaran V, Aigner A, et al. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. Eur Heart J. 2022;43(6):518–533. doi:10.1093/eurheartj/ehab644.
   PubMed Web of Science ®Google Scholar
• Meijnikman AS, Davids M, Herrema H, Aydin O, Tremaroli V, Rios-Morales M, Levels H, Bruin S, de Brauw M, Verheij J, et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat Med. 2022;28(10):2100–2106. doi:10.1038/s41591-022-02016-6.
   PubMed Web of Science ®Google Scholar
• Kodaman N, Pazos A, Schneider BG, Piazuelo MB, Mera R, Sobota RS, Sicinschi LA, Shaffer CL, Romero-Gallo J, de Sablet T, et al. Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proc Natl Acad Sci U S A. 2014;111(4):1455–1460. doi:10.1073/pnas.1318093111.
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–415. doi:10.1056/NEJMoa1205037.
   PubMed Web of Science ®Google Scholar
• Morad G, Helmink B, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309–5337. doi:10.1016/j.cell.2021.09.020.
   PubMed Web of Science ®Google Scholar
• Hanssen NMJ, de Vos WM, Nieuwdorp M. Fecal microbiota transplantation in human metabolic diseases: from a murky past to a bright future? Cell Metab. 2021;33(6):1098–1110. doi:10.1016/j.cmet.2021.05.005.
   PubMed Web of Science ®Google Scholar
• L C, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol. 2020;115(7):1055–1065. doi:10.14309/ajg.0000000000000661.
   PubMed Web of Science ®Google Scholar
• Witjes JJ, Smits LP, Pekmez CT, Prodan A, Meijnikman AS, Troelstra MA, Bouter KEC, Herrema H, Levin E, Holleboom AG, et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis. Hepatol Commun. 2020;4(11):1578–1590. doi:10.1002/hep4.1601.
   PubMed Web of Science ®Google Scholar
• Schmidt TSB, Li SS, Maistrenko OM, Akanni W, Coelho LP, Dolai S, Fullam A, Glazek AM, Hercog R, Herrema H, et al. Drivers and determinants of strain dynamics following fecal microbiota transplantation. Nat Med. 2022;28(9):1902–1912. doi:10.1038/s41591-022-01913-0.
   PubMed Web of Science ®Google Scholar
• De Groot P, Scheithauer T, Bakker GJ, Prodan A, Levin E, Khan MT, Herrema H, Ackermans M, Serlie MJM, de Brauw M, et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut. 2019;69(3):502–512. doi:10.1136/gutjnl-2019-318320.
   PubMed Web of Science ®Google Scholar
• Basson AR, Zhou Y, Seo B, Rodriguez-Palacios A, Cominelli F. Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease. Transl Res. 2020;226:1–11. doi:10.1016/j.trsl.2020.05.008.
   PubMed Web of Science ®Google Scholar
• Wilson BC, Vatanen T, Cutfield WS, O’Sullivan JM. The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front Cell Infect Microbiol. 2019;9. doi:10.3389/fcimb.2019.00002.
   Web of Science ®Google Scholar
• Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514. doi:10.1038/nrgastro.2014.66.
   PubMed Web of Science ®Google Scholar
• Bhathena J, Martoni C, Kulamarva A, Tomaro-Duchesneau C, Malhotra M, Paul A, Urbanska AM, Prakash S. Oral probiotic microcapsule formulation ameliorates non-alcoholic fatty liver disease in bio F1B golden Syrian hamsters. PLoS One. 2013;8(3):e58394. doi:10.1371/journal.pone.0058394.
   PubMed Web of Science ®Google Scholar
• Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, Meli R. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr. 2009;139(5):905–911. doi:10.3945/jn.108.101808.
   PubMed Web of Science ®Google Scholar
• Xue L, He J, Gao N, Lu X, Li M, Wu X, Liu Z, Jin Y, Liu J, Xu J, et al. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep. 2017;7(1). doi:10.1038/srep45176.
   Google Scholar
• Xiao MW, Lin SX, Shen ZH, Luo WW, Wang XY. Systematic review with meta-analysis: the effects of probiotics in nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2019;2019:1–19. doi:10.1155/2019/1484598.
   Web of Science ®Google Scholar
• Tang Y, Huang J, Zhang WY, Qin S, Yang YX, Ren H, Yang Q-B, Hu H. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2019;12:175628481987804. doi:10.1177/1756284819878046.
   Web of Science ®Google Scholar
• O’Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol. 2017;2(5):1–6. doi:10.1038/nmicrobiol.2017.57.
   Web of Science ®Google Scholar
• Ueda A, Shinkai S, Shiroma H, Taniguchi Y, Tsuchida S, Kariya T, Kawahara T, Kobayashi Y, Kohda N, Ushida K, et al. Identification of faecalibacterium prausnitzii strains for gut microbiome-based intervention in alzheimer’s-type dementia. Cell Rep Med. 2021;2(9):100398. doi:10.1016/j.xcrm.2021.100398.
   PubMedGoogle Scholar
• Wang Y, et al. Safety evaluation of a novel strain of bacteroides fragilis. Front Microbiol. 2017;8:435. doi:10.3389/fmicb.2017.00435.
   PubMed Web of Science ®Google Scholar
• Koopen A, Witjes J, Wortelboer K, Majait S, Prodan A, Levin E, Herrema H, Winkelmeijer M, Aalvink S, Bergman JJGHM, et al. Duodenal anaerobutyricum soehngenii infusion stimulates GLP-1 production, ameliorates glycaemic control and beneficially shapes the duodenal transcriptome in metabolic syndrome subjects: a randomised double-blind placebo-controlled cross-over study. Gut. 2022;71:1577–1587. doi:10.1136/gutjnl-2020-323297.
   PubMed Web of Science ®Google Scholar
• Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, et al. Supplementation with akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096–1103. doi:10.1038/s41591-019-0495-2.
   PubMed Web of Science ®Google Scholar
• Hitch TCA, et al. Microbiome-based interventions to modulate gut ecology and the immune system. Mucosal Immunol. 2022;15(6):1095–1113. doi:10.1038/s41385-022-00564-1.
   PubMed Web of Science ®Google Scholar
• Moens F, Van den Abbeele P, Basit AW, Dodoo C, Chatterjee R, Smith B, Gaisford S. A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro. Int J Pharm. 2019;555:1–10. doi:10.1016/j.ijpharm.2018.11.020.
   PubMedGoogle Scholar
• Hendrikx T, Duan Y, Wang Y, Oh J-H, Alexander LM, Huang W, Stärkel P, Ho SB, Gao B, Fiehn O, et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut. 2019;68(8):1504–1515. doi:10.1136/gutjnl-2018-317232.
   PubMed Web of Science ®Google Scholar
• Duan FF, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes. 2015;64:1794–1803. doi:10.2337/db14-0635.
   PubMed Web of Science ®Google Scholar
• Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125(6):1401–1412. doi:10.1093/jn/125.6.1401.
   PubMed Web of Science ®Google Scholar
• Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastro Hepat. 2017;14(8):491–502. doi:10.1038/nrgastro.2017.75.
   PubMed Web of Science ®Google Scholar
• Macfarlane S, Macfarlane GT, Cummings JH. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther. 2006;24(5):701–714. doi:10.1111/j.1365-2036.2006.03042.x.
   PubMed Web of Science ®Google Scholar
• Busserolles J, Gueux E, Rock E, Demigné C, Mazur A, Rayssiguier Y. Oligofructose protects against the hypertriglyceridemic and pro-oxidative effects of a high fructose diet in rats. J Nutr. 2003;133(6):1903–1908. doi:10.1093/jn/133.6.1903.
   PubMed Web of Science ®Google Scholar
• Daubioul C, Rousseau N, Taper H, Declerck B, Delzenne N, Demeure R, Gallez B. Dietary fructans, but not cellulose, decrease triglyceride accumulation in the liver of obese Zucker fa/fa rats. J Nutr. 2002;132(5):967–973. doi:10.1093/jn/132.5.967.
   PubMed Web of Science ®Google Scholar
• Delzenne NM, Daubioul C, Neyrinck A, Lasa M, Taper HS. Inulin and oligofructose modulate lipid metabolism in animals: review of biochemical events and future prospects. Br J Nutr. 2002;87(S2):S255–S259. doi:10.1079/BJN/2002545.
   PubMed Web of Science ®Google Scholar
• Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr. 2005;59(5):723–726. doi:10.1038/sj.ejcn.1602127.
   PubMed Web of Science ®Google Scholar
• Bomhof MR, Parnell JA, Ramay HR, Crotty P, Rioux KP, Probert CS, Jayakumar S, Raman M, Reimer RA. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr. 2019;58(4):1735–1745. doi:10.1007/s00394-018-1721-2.
   PubMed Web of Science ®Google Scholar
• Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, Sanders ME, Shamir R, Swann JR, Szajewska H, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649–667. doi:10.1038/s41575-021-00440-6.
   PubMed Web of Science ®Google Scholar
• Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol. 2021;19(2):77–94. doi:10.1038/s41579-020-0438-4.
   PubMed Web of Science ®Google Scholar
• Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. 2021;70:1174. doi:10.1136/gutjnl-2020-323071.
   PubMed Web of Science ®Google Scholar
• Vinolo MAR, Rodrigues HG, Festuccia WT, Crisma AR, Alves VS, Martins AR, Amaral CL, Fiamoncini J, Hirabara SM, Sato FT, et al. Tributyrin attenuates obesity-associated inflammation and insulin resistance in high-fat-fed mice. Am J Physiol Endocrinol Metab. 2012;303(2):E272–E282. doi:10.1152/ajpendo.00053.2012.
   PubMed Web of Science ®Google Scholar
• Juanola O, Ferrusquía-Acosta J, García-Villalba R, Zapater P, Magaz M, Marín A, Olivas P, Baiges A, Bellot P, Turon F, et al. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. Faseb J. 2019;33(10):11595–11605. doi:10.1096/fj.201901327R.
   PubMed Web of Science ®Google Scholar
• van der Beek CM, Bloemen JG, van den Broek MA, Lenaerts K, Venema K, Buurman WA, Dejong CH. Hepatic uptake of rectally administered butyrate prevents an increase in systemic butyrate concentrations in humans1–3. J Nutr. 2015;145(9):2019–2024. doi:10.3945/jn.115.211193.
   PubMed Web of Science ®Google Scholar
• Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, Dallinga–Thie GM, Ackermans MT, Serlie MJ, Oozeer R, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–916.e7. doi:10.1053/j.gastro.2012.06.031.
   PubMed Web of Science ®Google Scholar
• Reijnders D, Goossens G, Hermes GA, Neis EJG, van der Beek C, Most J, Holst J, Lenaerts K, Kootte R, Nieuwdorp M, et al. Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial. Cell Metab. 2016;24(1):63–74. doi:10.1016/j.cmet.2016.06.016.
   PubMed Web of Science ®Google Scholar
• Smits LP, Kootte RS, Levin E, Prodan A, Fuentes S, Zoetendal EG, Wang Z, Levison BS, Cleophas MCP, Kemper EM, et al. Effect of vegan fecal microbiota transplantation on carnitine- and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome. J Am Heart Assoc. 2018;7(7). doi:10.1161/JAHA.117.008342.
   PubMed Web of Science ®Google Scholar
• Jin M, Kalainy S, Baskota N, Chiang D, Deehan EC, McDougall C, Tandon P, Martínez I, Cervera C, Walter J, et al. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. Liver Int. 2019;39(8):1437–1447. doi:10.1111/liv.14106.
   PubMed Web of Science ®Google Scholar
• Canfora EE, van der Beek CM, Jocken JWE, Goossens GH, Holst JJ, Olde Damink SWM, Lenaerts K, Dejong CHC, Blaak EE. Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial. Sci Rep. 2017;7(1). doi:10.1038/s41598-017-02546-x.
   Google Scholar
• Coppola S, Nocerino R, Paparo L, Bedogni G, Calignano A, Di Scala C, de Giovanni di Santa Severina AF, De Filippis F, Ercolini D, Berni Canani R. Therapeutic effects of butyrate on pediatric obesity: a randomized clinical trial. JAMA Netw Open. 2022;5(12):e2244912–e2244912. doi:10.1001/jamanetworkopen.2022.44912.
   PubMed Web of Science ®Google Scholar
• Teunis C, Nieuwdorp M, Hanssen N. Interactions between Tryptophan metabolism, the gut microbiome and the immune system as potential drivers of non-alcoholic fatty liver disease (NAFLD) and metabolic diseases. Metabolites. 2022;12(6):514. doi:10.3390/metabo12060514.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Reddy KR, O’Leary JG, Vargas HE, Lai JC, Kamath PS, Tandon P, Wong F, Subramanian RM, Thuluvath P, et al. Serum levels of metabolites produced by intestinal microbes and lipid moieties independently associated with acute-on-chronic liver failure and death in patients with cirrhosis. Gastroenterology. 2020;159(5):1715–1730.e12. doi:10.1053/j.gastro.2020.07.019.
   PubMed Web of Science ®Google Scholar
• Clària J, Moreau R, Fenaille F, Amorós A, Junot C, Gronbaek H, Coenraad MJ, Pruvost A, Ghettas A, Chu‐Van E, et al. Orchestration of tryptophan-kynurenine pathway, acute decompensation, and acute-on-chronic liver failure in cirrhosis. Hepatology. 2019;69(4):1686–1701. doi:10.1002/hep.30363.
   PubMed Web of Science ®Google Scholar
• Taleb S. Tryptophan dietary impacts gut barrier and metabolic diseases. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.02113.
   PubMed Web of Science ®Google Scholar
• Hendrikx T, Schnabl B. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. J Intern Med. 2019;286:32–40. doi:10.1111/joim.12892.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Shi Y, Chen C, Wu F, Chen Z. A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases. Ann Transl Med. 2021;9:174–174. doi:10.21037/atm-20-3594.
   PubMed Web of Science ®Google Scholar
• Wahlstr?m A, Sayin SI, Marschall HU, B?ckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50. doi:10.1016/j.cmet.2016.05.005.
   PubMed Web of Science ®Google Scholar
• Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731–744. doi:10.1016/S0092-8674(00)00062-3.
   PubMed Web of Science ®Google Scholar
• De Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013;17(5):657–669. doi:10.1016/j.cmet.2013.03.013.
   PubMed Web of Science ®Google Scholar
• Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, Luketic VA, Siddiqui MS, Boyett S, Min H-K, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology. 2018;67(2):534–548. doi:10.1002/hep.29359.
   PubMed Web of Science ®Google Scholar
• Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58(5):949–955. doi:10.1016/j.jhep.2013.01.003.
   PubMed Web of Science ®Google Scholar
• Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65:350–362. doi:10.1002/hep.28709.
   PubMed Web of Science ®Google Scholar
• Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, et al. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. Lancet Gastroenterol Hepatol. 2019;4(10):781–793. doi:10.1016/S2468-1253(19)30184-0.
   PubMed Web of Science ®Google Scholar
• Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, Strobel B, Schubert T-L, Riedl F, Mitteregger D, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol. 2017;66(4):724–733. doi:10.1016/j.jhep.2016.12.005.
   PubMed Web of Science ®Google Scholar
• Friedman ES, Li Y, Shen TCD, Jiang J, Chau L, Adorini L, Babakhani F, Edwards J, Shapiro D, Zhao C, et al. FXR-Dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid. Gastroenterology. 2018;155(6):1741. doi:10.1053/j.gastro.2018.08.022.
   PubMed Web of Science ®Google Scholar
• Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–609. doi:10.1002/hep.26093.
   PubMed Web of Science ®Google Scholar
• Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, Zhao X, Li N, Li S, Xue G, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 2019;30(4):675–688.e7. doi:10.1016/j.cmet.2019.08.018.
   PubMed Web of Science ®Google Scholar
• WK S, V T, SS C, AM D. Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. Semin Liver Dis. 2009;29(2):200–210. doi:10.1055/s-0029-1214375.
   PubMed Web of Science ®Google Scholar
• Diehl AM, Day CC, Longo DL. Pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377(21):2063–2072. doi:10.1056/NEJMra1503519.
   PubMed Web of Science ®Google Scholar
• Thursz M, Gual A, Lackner C, Mathurin P, Moreno C, Spahr L, Sterneck M, Cortez-Pinto H. EASL Clinical Practice Guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69(1):154–181. doi:10.1016/j.jhep.2018.03.018.
   PubMed Web of Science ®Google Scholar
• Krebs HA, Perkins JR. The physiological role of liver alcohol dehydrogenase. Biochem J. 1970;118(4):635–644. doi:10.1042/bj1180635.
   PubMed Web of Science ®Google Scholar
• Wilson DF, M MF. Ethanol metabolism: the good, the bad, and the ugly. Med Hypotheses. 2020;140:109638. doi:10.1016/j.mehy.2020.109638.
   PubMed Web of Science ®Google Scholar
• Meijnikman AS, Herrema H, Scheithauer TPM, Kroon J, Nieuwdorp M, Groen AK. Evaluating causality of cellular senescence in non-alcoholic fatty liver disease. JHEP Reports. 2021;3(4):100301. doi:10.1016/j.jhepr.2021.100301.
   PubMedGoogle Scholar
• Meijnikman AS, van Olden CC, Aydin Ö, Herrema H, Kaminska D, Lappa D, Männistö V, Tremaroli V, Olofsson LE, de Brauw M, et al. Hyperinsulinemia is highly associated with markers of hepatocytic senescence in two independent cohorts. Diabetes. 2022; (9):1929–1936. doi:10.2337/DB21-1076.
   PubMed Web of Science ®Google Scholar
• Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology. 2000;119:1340–1347. doi:10.1053/gast.2000.19267.
   PubMed Web of Science ®Google Scholar
• de Medeiros IC, de Lima JG. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease? – a mechanistic hypothesis. Med Hypotheses. 2015;85(2):148–152. doi:10.1016/j.mehy.2015.04.021.
   PubMed Web of Science ®Google Scholar
• Simic M, Ajdukovic N, Veselinovic I, Mitrovic M, Djurendic-Brenesel M. Endogenous ethanol production in patients with diabetes mellitus as a medicolegal problem. Forensic Sci Int. 2012;216(1–3):97–100. doi:10.1016/j.forsciint.2011.09.003.
   PubMed Web of Science ®Google Scholar
• Förster AH, Gescher J. Metabolic engineering of Escherichia coli for production of mixed-acid fermentation end products. Front Bioeng Biotechnol. 2014;2:16. doi:10.3389/fbioe.2014.00016.
   PubMedGoogle Scholar
• Elshaghabee F, Bockelmann W, Meske D, de Vrese M, Walte H-G, Schrezenmeir J, Heller KJ. Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions. Front Microbiol. 2016;7. doi:10.3389/fmicb.2016.00047.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Sikaroodi M, Shamsaddini A, Henseler Z, Santiago-Rodriguez T, Acharya C, Fagan A, Hylemon PB, Fuchs M, Gavis E, et al. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut. 2021;70(6):1162–1173. doi:10.1136/gutjnl-2020-322470.
   PubMed Web of Science ®Google Scholar
• Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019;575(7783):505–511. doi:10.1038/s41586-019-1742-x.
   PubMed Web of Science ®Google Scholar
• Spence JD, Pilote L. Importance of sex and gender in atherosclerosis and cardiovascular disease. Atherosclerosis. 2015;241(1):208–210. doi:10.1016/j.atherosclerosis.2015.04.806.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol. 2010;9(4):402–409. doi:10.1016/S1665-2681(19)31616-3.
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34(3):309–338. doi:10.1210/er.2012-1055.
   PubMed Web of Science ®Google Scholar
• Balakrishnan M, Patel P, Dunn-Valadez S, Dao C, et al, Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(1):61–71.e15. doi:10.1016/j.cgh.2020.04.067.
   PubMed Web of Science ®Google Scholar
• Allen AM, Therneau TM, Mara KC, Larson JJ, Watt KD, Hayes SN, Kamath PS. Women with nonalcoholic fatty liver disease lose protection against cardiovascular disease: a longitudinal cohort study. Am J Gastroenterol. 2019;114(11):1764–1771. doi:10.14309/ajg.0000000000000401.
   PubMed Web of Science ®Google Scholar
• Markle JGM, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, von Bergen M, McCoy KD, Macpherson AJ, Danska JS. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;1979(6123):1084–1088. doi:10.1126/science.1233521.
   Google Scholar
• Org E, et al. Sex differences and hormonal effects on gut microbiota composition in mice. Gut Microbes. 2016;7(4):313–322. doi:10.1080/19490976.2016.1203502.
   PubMed Web of Science ®Google Scholar
• Shin JH, Park Y-H, Sim M, Kim S-A, Joung H, Shin D-M. Serum level of sex steroid hormone is associated with diversity and profiles of human gut microbiome. Res Microbiol. 2019;170(4–5):192–201. doi:10.1016/j.resmic.2019.03.003.
   PubMed Web of Science ®Google Scholar
• Shi J, Yang Y, Xu W, Cai H, Wu J, Long J, Cai Q, Zheng W, Flynn CR, Shu X-O, et al. Sex-specific associations between gut microbiome and non-alcoholic fatty liver disease among urban Chinese adults. Microorganisms. 2021;9(10):2118. doi:10.3390/microorganisms9102118.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol. 2022;76(6):1263–1278. doi:10.1016/j.jhep.2022.04.002.
   PubMed Web of Science ®Google Scholar